Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Depreciation & Amortization (CF) (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $396000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 13.54% to $396000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a 18.97% decrease, with the full-year FY2025 number at $1.7 million, down 20.19% from a year prior.
  • Depreciation & Amortization (CF) was $396000.0 for Q4 2025 at Pliant Therapeutics, down from $400000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $635000.0 in Q2 2024 to a low of $396000.0 in Q4 2025.
  • A 5-year average of $452550.0 and a median of $452000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 58.75% in 2024, then decreased 28.82% in 2025.
  • Pliant Therapeutics' Depreciation & Amortization (CF) stood at $400000.0 in 2021, then increased by 8.0% to $432000.0 in 2022, then rose by 7.41% to $464000.0 in 2023, then fell by 1.29% to $458000.0 in 2024, then dropped by 13.54% to $396000.0 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Depreciation & Amortization (CF) are $396000.0 (Q4 2025), $400000.0 (Q3 2025), and $452000.0 (Q2 2025).